TB-500 vs BPC-157: Which Healing Peptide Should Researchers Choose in 2026?
Share
BPC-157 and TB-500 are the two most-cited "healing peptides" in modern research literature. They show up together so often that many India researchers ask the same question: which one should I choose — or should I stack both? This 2026 guide compares them side-by-side from a research-peptide selection perspective.
India dispatch · 4-in-1 vial · Best per-peptide value
Get both TB-500 + BPC-157 in one vial — KLOW ₹13,999
80 mg lyophilised blend: GHK-Cu + TB-500 + BPC-157 + KPV · Single reconstitution · COD accepted
Use code RESEARCH10 at checkout for 10% off your peptide order
Quick comparison table
| Attribute | BPC-157 | TB-500 |
|---|---|---|
| Class | Pentadecapeptide (15 aa) | Synthetic fragment of Thymosin Beta-4 |
| Approx. molecular weight | ~1,419 Da | ~890 Da (LKKTETQ region) |
| CAS | 137525-51-0 | (fragment; parent Tβ4 CAS 77591-33-4) |
| Origin | Synthetic pentadecapeptide from gastric-juice protein sequence | Synthetic fragment of the 43-aa Thymosin Beta-4 protein |
| Form supplied | Lyophilised powder, sealed vial | Lyophilised powder, sealed vial |
| Typical OMNIPOTENT INR price (10 mg) | ₹9,499 | ₹12,999 |
| Buy | BPC-157 India | TB-500 India |
What is BPC-157?
BPC-157 is a synthetic 15-amino-acid peptide (pentadecapeptide) corresponding to a partial sequence of a Body Protection Compound found in gastric juice. It is one of the most studied compounds in the modern "tissue protection" research category, with extensive preclinical literature on its effects across multiple tissue types. Sold as a lyophilised powder in 5 mg / 10 mg vials. See our full BPC-157 India guide.
What is TB-500?
TB-500 is a synthetic peptide fragment derived from the sequence of Thymosin Beta-4 (Tβ4), a 43-amino-acid protein involved in actin-binding cellular processes. TB-500 is supplied as a lyophilised reference compound in 5 mg / 10 mg vials and is widely cited in research on cellular migration and tissue-healing pathways. Important: TB-500 is the synthetic fragment; full-length Thymosin Beta-4 protein is a distinct research tool.
BPC-157 vs TB-500 — the key differences
- Sequence origin: BPC-157 derives from a gastric-juice protein sequence; TB-500 derives from Thymosin Beta-4.
- Molecular size: BPC-157 is ~1,419 Da; TB-500 fragment is ~890 Da.
- Mechanism focus in literature: BPC-157 literature emphasises vascular and gastrointestinal tissue contexts; TB-500 literature emphasises actin-binding and cell migration.
- Half-life context: Both peptides have short in-vivo half-lives in published preclinical work; protocol design typically accounts for this.
Why researchers often use both
BPC-157 and TB-500 are biochemically distinct but appear together so often in tissue-healing research that combinatorial protocols have become standard. The mechanistic rationale in the published literature is non-overlapping activity — i.e., two different molecular pathways studied in parallel. For India researchers running combinatorial work, sourcing both individually or sourcing the pre-formulated KLOW 4-in-1 blend (which co-formulates GHK-Cu + TB-500 + BPC-157 + KPV in a single 80 mg vial at ₹13,999) are the two common purchase patterns.
Pricing comparison in India — 2026 benchmarks
- BPC-157 10 mg: OMNIPOTENT ₹9,499 | fair range ₹8,500 – ₹14,000
- TB-500 5 mg: OMNIPOTENT ₹6,999 | fair range ₹6,000 – ₹10,000
- TB-500 10 mg: OMNIPOTENT ₹12,999 | fair range ₹11,000 – ₹18,000
- KLOW 80 mg (combo): OMNIPOTENT ₹13,999 — most cost-effective if you want both peptides plus GHK-Cu and KPV
Lyophilised stability — same for both
Both BPC-157 and TB-500 are stable as lyophilised powders at 2–8 °C for 24+ months in sealed vials. Both are reconstituted with Bacteriostatic Water (0.9% benzyl alcohol) immediately before laboratory use and refrigerated post-reconstitution. India's summer ambient temperatures make refrigerated storage on arrival essential for both.
What about KLOW — the combined option?
KLOW is OMNIPOTENT's 4-in-1 research peptide blend that co-formulates GHK-Cu + TB-500 + BPC-157 + KPV in a single 80 mg lyophilised vial at ₹13,999. For India researchers running combinatorial healing-research protocols, the per-peptide economics typically work out cheaper than buying each compound individually, and the single-vial reconstitution simplifies bench work. Read our full KLOW Blend Explained guide.
Which should you choose?
This depends entirely on your research model and reference literature:
- If you're replicating published BPC-157 work: Buy BPC-157 as a standalone.
- If you're replicating published TB-500 / Thymosin Beta-4 fragment work: Buy TB-500 as a standalone.
- If you're running combinatorial protocols: Buy both, or consider the KLOW 4-in-1 blend for cost-efficiency.
FAQ
Is BPC-157 the same as Thymosin Beta-4?
No. BPC-157 is a synthetic pentadecapeptide from a gastric-juice protein sequence. TB-500 is a synthetic fragment of Thymosin Beta-4. They are biochemically distinct compounds.
Can I stack BPC-157 and TB-500 in laboratory research?
Many published research protocols use them in parallel because their mechanisms are non-overlapping. For researchers wanting a single-vial option, the KLOW blend co-formulates both alongside GHK-Cu and KPV.
Which is cheaper per-peptide in India?
TB-500 and BPC-157 individually run in similar INR ranges (₹6,999–12,999 depending on vial size). For both plus GHK-Cu and KPV, the KLOW blend at ₹13,999 is the most cost-effective single SKU.
This article is provided for informational purposes only. Research peptides referenced are supplied strictly as chemical reference standards for in-vitro laboratory research. They are not drugs, foods, cosmetics, or supplements and are not approved for human or veterinary use by CDSCO, FSSAI, the US FDA, or any other regulatory body.